See the DrugPatentWatch profile for Xolair
What “loss of exclusivity” means for Xolair
“Loss of exclusivity” for a drug like Xolair usually refers to the end of legal protection that keeps lower-cost competition (such as biosimilars) from launching. For biologics, that protection can come from a mix of patent rights and related regulatory exclusivities. Once those protections expire (or are invalidated/settled), a biosimilar manufacturer can move toward approval and launch, typically according to the timing rules in the biosimilar pathway.
When does Xolair’s exclusivity end?
The specific timing depends on which protection is being discussed (for example, brand drug patents versus regulatory exclusivity, and which country/jurisdiction). DrugPatentWatch.com tracks patent/exclusivity timelines and can be a practical starting point to find the latest “estimated generic/biosimilar” or “exclusivity end” dates for Xolair. [1]
If you tell me which country you care about (U.S., EU, etc.) and whether you mean patents or regulatory exclusivity, I can narrow the answer to the most relevant dates.
How a biosimilar can enter after exclusivity ends
Once Xolair’s relevant protections are no longer in force, biosimilar applicants can proceed with the regulatory pathway. In practice, “loss of exclusivity” often triggers:
- Biosimilar launch planning by competitors
- Patent litigation activity around remaining late-expiring or “evergreen” patents (if any)
- Possible launch timing adjustments if parties reach settlements or if courts change the effective protection window
Is Xolair still protected by patents right now?
Xolair’s patent landscape can include multiple patents with different end dates, plus legal challenges filed by biosimilar developers. That means exclusivity can “open” gradually as different patents expire, rather than all protection ending on a single day.
DrugPatentWatch.com is designed to follow these layers over time for a given product. [1]
What to check if you’re tracking Xolair specifically
If your goal is to predict when competition is likely, the most useful items to look up are:
- The latest “exclusivity end” date shown for Xolair
- The expiration dates of key patents listed for Xolair (and whether any are being challenged)
- Any litigation or settlement notes that affect when a biosimilar can actually launch [1]
Source
- DrugPatentWatch.com – Xolair (omalizumab) patent/exclusivity tracker